Effectiveness of anti-interleukin 23 biologic drugs in psoriasis patients who failed anti-interleukin 17 regimens. A real-life experience

被引：33

作者：

Bonifati, Claudio ^{[1
]}

Morrone, Aldo ^{[1
]}

Cristaudo, Antonio ^{[1
]}

Graceffa, Dario ^{[1
]}

机构：

[1] IRCCS, San Gallicano Dermatol Inst, Ctr Study & Treatment Psoriasis, Dept Clin Dermatol, Rome, Italy

来源：

DERMATOLOGIC THERAPY | 2021年 / 34卷 / 01期

关键词：

anti‐ interleukin; 17; 23; biologics; psoriasis; switch; INDEX;

D O I：

10.1111/dth.14584

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

Among the most recent biologic drugs available for psoriasis therapy, those targeting interleukin-17 (secukinumab and ixekizumab) or its receptor (brodalumab) have been shown to be quickly effective. However, in those patients who failed one or more of the above-cited drugs, real-life data on the effectiveness of switching to one anti-interleukin-23 biologic (guselkumab, risankizumab, or tildrakizumab) are very scarce. Here, we report our experience in treating 12 multi-failure psoriatic patients, prospectively followed-up over 6 months, who showed a significant improvement in their psoriasis after switching from an anti-interleukn-17 to an anti-interleukin-23 drug.

引用

页数：4

共 12 条

[1] A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial [J].

Blauvelt, A. ;

Papp, K. ;

Gottlieb, A. ;

Jarell, A. ;

Reich, K. ;

Maari, C. ;

Gordon, K. B. ;

Ferris, L. K. ;

Langley, R. G. ;

Tada, Y. ;

Lima, R. G. ;

Elmaraghy, H. ;

Gallo, G. ;

Renda, L. ;

Park, S. Y. ;

Burge, R. ;

Bagel, J. ;

Devani, Alim ;

Vender, Ronald ;

Lomaga, Mark A. ;

Delorme, Isabelle ;

Hong, Chih-Ho ;

Langley, Richard L. ;

Albrecht, Lorne ;

Guenther, Lyn ;

Maari, Catherine ;

Papp, Kim ;

Ohson, Kamal K. Singh ;

Barber, Kirk ;

Lynde, Charles ;

Gupta, Aditya ;

Rosoph, Leslie ;

Gauthier, Jean-Sebastien ;

Gooderham, Melinda ;

Wasel, Norman ;

Raman, Mani ;

Wiseman, Marni ;

Greenstein, David ;

Jarell, Abel ;

Moon, Charles ;

Clark, Lani ;

Jazayeri, Sadra Sasha ;

Bukhalo, Michael ;

Moore, Angela ;

Hamilton, Tiffani K. ;

Gewirtzman, Aron ;

Hazan, Lydie ;

Crowley, Jeffrey ;

Teller, Craig ;

Zirwas, Matthew .

BRITISH JOURNAL OF DERMATOLOGY, 2020, 182 (06) :1348-1358

[2] DERMATOLOGY LIFE QUALITY INDEX (DLQI) - A SIMPLE PRACTICAL MEASURE FOR ROUTINE CLINICAL USE [J].

FINLAY, AY ;

KHAN, GK .

CLINICAL AND EXPERIMENTAL DERMATOLOGY, 1994, 19 (03) :210-216

[3] SEVERE PSORIASIS - ORAL THERAPY WITH A NEW RETINOID [J].

FREDRIKSSON, T ;

PETTERSSON, U .

DERMATOLOGICA, 1978, 157 (04) :238-244

[4] Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials [J].

Gordon, Kenneth B. ;

Strober, Bruce ;

Lebwohl, Mark ;

Augustin, Matthias ;

Blauvelt, Andrew ;

Poulin, Yves ;

Papp, Kim A. ;

Sofen, Howard ;

Puig, Lluis ;

Foley, Peter ;

Ohtsuki, Mamitaro ;

Flack, Mary ;

Geng, Ziqian ;

Gu, Yihua ;

Valdes, Joaquin M. ;

Thompson, Elizabeth H. Z. ;

Bachelez, Herve .

LANCET, 2018, 392 (10148) :650-661

[5] Secukinumab Use in Patients with Moderate to Severe Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis in Real-World Setting in Europe: Baseline Data from SERENA Study [J].

Kiltz, Uta ;

Sfikakis, Petros P. ;

Gaffney, Karl ;

Sator, Paul-Gunther ;

von Kiedrowski, Ralph ;

Bounas, Andreas ;

Gullick, Nicola ;

Conrad, Curdin ;

Rigopoulos, Dimitris ;

Lespessailles, Eric ;

Romanelli, Marco ;

Ghislain, Pierre-Dominique ;

Brandt-Juergens, Jan ;

Rashkov, Rasho ;

Aassi, Maher ;

Orsenigo, Roberto ;

Perella, Chiara ;

Pournara, Effie ;

Gathmann, Sven ;

Jagiello, Piotr ;

Veit, Justyna ;

Augustin, Matthias .

ADVANCES IN THERAPY, 2020, 37 (06) :2865-2883

[6] Evaluating psoriasis with psoriasis area and severity index, psoriasis global assessment, and lattice system physician's global assessment [J].

Langley, RG ;

Ellis, CN .

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2004, 51 (04) :563-569

[7] Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis [J].

Lebwohl, M. ;

Strober, B. ;

Menter, A. ;

Gordon, K. ;

Weglowska, J. ;

Puig, L. ;

Papp, K. ;

Spelman, L. ;

Toth, D. ;

Kerdel, F. ;

Armstrong, A. W. ;

Stingl, G. ;

Kimball, A. B. ;

Bachelez, H. ;

Wu, J. J. ;

Crowley, J. ;

Langley, R. G. ;

Blicharski, T. ;

Paul, C. ;

Lacour, J. -P. ;

Tyring, S. ;

Kircik, L. ;

Chimenti, S. ;

Duffin, K. C. ;

Bagel, J. ;

Koo, J. ;

Aras, G. ;

Li, J. ;

Song, W. ;

Milmont, C. E. ;

Shi, Y. ;

Erondu, N. ;

Klekotka, P. ;

Kotzin, B. ;

Nirula, A. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (14) :1318-1328

[8] Efficacy of a second interleukin 17 inhibitor in patients with psoriasis: A systematic review and meta-analysis [J].

Loft, Nikolai ;

Halling, Anne-Sofie ;

Egeberg, Alexander ;

Skov, Lone .

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 84 (01) :130-138

[9] Users of biologics in clinical practice: would they be eligible for phase III clinical studies? Cohort Study in the French Psoriasis Registry PSOBIOTEQ [J].

Masson Regnault, M. ;

Castaneda-Sanabria, J. ;

Tran, M. H. T. Diep ;

Beylot-Barry, M. ;

Bachelez, H. ;

Beneton, N. ;

Chosidow, O. ;

Dupuy, A. ;

Joly, P. ;

Jullien, D. ;

Mahe, E. ;

Richard, M. -A. ;

Viguier, M. ;

Tubach, F. ;

Sbidian, E. ;

Paul, C. .

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2020, 34 (02) :293-300

[10] Efficacy and safety of risankizumab in psoriasis patients who failedanti-IL-17, anti-12/23 and/or antiIL-23: Preliminary data of a real-life 16-week retrospective study [J].

Megna, Matteo ;

Fabbrocini, Gabriella ;

Ruggiero, Angelo ;

Cinelli, Eleonora .

DERMATOLOGIC THERAPY, 2020, 33 (06)

← 1 2 →